Johnson & Johnson $JNJ Stock Position Trimmed by Sowell Financial Services LLC

Sowell Financial Services LLC decreased its position in shares of Johnson & Johnson (NYSE:JNJ) by 3.6% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 55,176 shares of the company’s stock after selling 2,062 shares during the quarter. Sowell Financial Services LLC’s holdings in Johnson & Johnson were worth $14,607,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the company. One Wealth Capital Management LLC boosted its stake in shares of Johnson & Johnson by 511.0% in the 3rd quarter. One Wealth Capital Management LLC now owns 5,010 shares of the company’s stock valued at $1,326,000 after purchasing an additional 4,190 shares during the last quarter. Lorne Steinberg Wealth Management Inc. grew its position in shares of Johnson & Johnson by 2.1% during the 3rd quarter. Lorne Steinberg Wealth Management Inc. now owns 39,472 shares of the company’s stock worth $10,450,000 after buying an additional 795 shares during the period. Evergreen Capital Management LLC raised its stake in shares of Johnson & Johnson by 2.3% during the third quarter. Evergreen Capital Management LLC now owns 67,727 shares of the company’s stock worth $17,930,000 after buying an additional 1,502 shares during the last quarter. Altura Wealth Advisors Inc. raised its stake in shares of Johnson & Johnson by 13.1% during the third quarter. Altura Wealth Advisors Inc. now owns 8,541 shares of the company’s stock worth $2,261,000 after buying an additional 988 shares during the last quarter. Finally, RWC Asset Management LLP lifted its holdings in Johnson & Johnson by 2.1% in the third quarter. RWC Asset Management LLP now owns 267,730 shares of the company’s stock valued at $70,879,000 after buying an additional 5,591 shares during the period. 69.55% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have issued reports on the stock. Stifel Nicolaus set a $260.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, July 15th. Morgan Stanley dropped their target price on shares of Johnson & Johnson from $294.00 to $292.00 and set an “overweight” rating for the company in a research report on Thursday, October 15th. Wall Street Zen downgraded Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Saturday, August 1st. Sanford C. Bernstein set a $270.00 price target on Johnson & Johnson in a research report on Thursday, October 15th. Finally, The Goldman Sachs Group reaffirmed a “buy” rating and set a $282.00 price objective on shares of Johnson & Johnson in a research note on Thursday, July 16th. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $275.92.

Insiders Place Their Bets

In other news, EVP Elizabeth Forminard sold 15,918 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $257.00, for a total value of $4,090,926.00. Following the sale, the executive vice president directly owned 16,994 shares in the company, valued at $4,367,458. This trade represents a 48.37% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Timothy Schmid sold 33,597 shares of the business’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the completion of the sale, the executive vice president directly owned 25,447 shares in the company, valued at approximately $6,991,308.78. This represents a 56.90% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 64,515 shares of company stock valued at $17,271,766 in the last quarter. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: JNJ is included among pharmaceutical companies with potential arthritis-treatment growth, supported by drug sales, clinical progress and regulatory expansion. This reinforces the outlook for its Innovative Medicine business and future cash generation. The Zacks Analyst Blog Highlights Eli Lilly, Novartis, Johnson & Johnson and AbbVie
• Positive Sentiment: The company will hold an Enterprise Business Review on December 8, when management is expected to provide additional detail on its Innovative Medicine and MedTech pipelines, long-term strategy and growth opportunities. The event could offer catalysts if the company raises confidence in future earnings. Johnson & Johnson to Host Enterprise Business Review
• Neutral Sentiment: JNJ has gained roughly 97% over three years, prompting investors to assess whether its valuation is supported by expected cash flow. Oncology trial developments and MedTech performance could materially influence that assessment. Johnson & Johnson Stock Trades At A Discount Following Its 97% Run
• Negative Sentiment: Ongoing attention to a talc-related charge adds legal and cash-flow uncertainty, while investors continue to monitor the broader talc litigation overhang. What Does the Talc Charge Mean for Johnson & Johnson Going Forward?
• Negative Sentiment: Reports of approximately $34.7 million in net ETF selling represent a modest technical headwind, although such flows do not necessarily reflect a change in JNJ’s fundamentals. Johnson & Johnson Sees $34.7 Million in Net ETF Selling
• Negative Sentiment: Pomerantz LLP is investigating potential claims on behalf of JNJ investors. The announcement does not establish wrongdoing, but it adds to headline and litigation risk. Investor Alert: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Johnson & Johnson

Johnson & Johnson Price Performance

JNJ opened at $271.17 on Thursday. The stock has a market cap of $652.78 billion, a P/E ratio of 41.09, a P/E/G ratio of 2.61 and a beta of 0.21. Johnson & Johnson has a 12 month low of $184.66 and a 12 month high of $281.07. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 0.44. The company has a fifty day simple moving average of $265.60 and a 200 day simple moving average of $246.26.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share for the quarter, beating the consensus estimate of $2.53 by $0.06. The company had revenue of $25.40 billion during the quarter, compared to analysts’ expectations of $25.38 billion. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The business’s quarterly revenue was up 5.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.80 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. On average, research analysts expect that Johnson & Johnson will post 11.12 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be given a dividend of $1.34 per share. The ex-dividend date of this dividend is Tuesday, November 24th. This represents a $5.36 dividend on an annualized basis and a yield of 2.0%. Johnson & Johnson’s dividend payout ratio is 81.21%.

Johnson & Johnson Profile

Johnson & Johnson (NYSE: JNJ) is a global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company develops and markets products and services for patients, healthcare professionals and institutions worldwide.

Johnson & Johnson operates through two principal segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals for areas such as immunology, oncology, neuroscience, infectious diseases and cardiovascular conditions.